A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
442 enrolled
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
Phase 1/2 Recruiting
58 enrolled
PROSPER
Phase 1/2 Recruiting
403 enrolled
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Phase 1/2 Recruiting
768 enrolled
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Phase 1/2 Recruiting
252 enrolled
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Phase 1/2 Recruiting
1,130 enrolled
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Phase 1/2 Recruiting
300 enrolled
Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma
Phase 1/2 Recruiting
126 enrolled
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
Phase 1/2 Recruiting
60 enrolled
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Phase 1/2 Recruiting
295 enrolled
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
Phase 1/2 Recruiting
31 enrolled
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
Phase 1/2 Recruiting
482 enrolled
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Phase 1/2 Recruiting
134 enrolled
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
Phase 1/2 Recruiting
220 enrolled
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
Phase 1/2 Recruiting
71 enrolled
Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
Phase 1/2 Recruiting
54 enrolled
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Phase 1/2 Recruiting
147 enrolled
EVEREST-2
Phase 1/2 Recruiting
474 enrolled
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Phase 1/2 Recruiting
159 enrolled
Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC
Phase 1/2 Recruiting
24 enrolled
SELECT-CAR-NK
Phase 1/2 Recruiting
85 enrolled
EBNK-ST-001
Phase 1/2 Recruiting
83 enrolled
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
Phase 1/2 Recruiting
400 enrolled
KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer
Phase 1/2 Recruiting
49 enrolled
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Phase 1/2 Recruiting
370 enrolled
A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
Phase 1/2 Recruiting
135 enrolled
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
Phase 1/2 Recruiting
110 enrolled
ODIN
Phase 1/2 Recruiting
43 enrolled
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
Phase 1/2 Recruiting
336 enrolled
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
Phase 1/2 Recruiting
220 enrolled
MK-9999-02A
Phase 1/2 Recruiting
220 enrolled
A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
Phase 1/2 Recruiting
334 enrolled
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
Phase 1/2 Recruiting
66 enrolled
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Phase 1/2 Recruiting
112 enrolled
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
Phase 1/2 Recruiting
294 enrolled
BetaBart
Phase 1/2 Recruiting
61 enrolled
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
Phase 1/2 Recruiting
100 enrolled
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
Phase 1/2 Recruiting
180 enrolled
A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
Phase 1/2 Recruiting
360 enrolled
ProbeTILity
Phase 1/2 Recruiting
12 enrolled
A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation
Phase 1/2 Recruiting
126 enrolled
A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC
Phase 1/2 Recruiting
66 enrolled
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed
Phase 1/2 Recruiting
320 enrolled
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Phase 1/2 Recruiting
754 enrolled
A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer
Phase 1/2 Recruiting
53 enrolled
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
270 enrolled
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Phase 1/2 Recruiting
540 enrolled
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Phase 1/2 Recruiting
126 enrolled
DENALI-1
Phase 1/2 Recruiting
240 enrolled
PHANTOM
Phase 1/2 Recruiting
26 enrolled